

AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph beginning at page 12, line 9, as follows:

The invention also relates to the conjugates obtained by covalent coupling of the peptides according to the invention (or of the above-mentioned oligomers) to physiologically acceptable and non-toxic (natural or synthetic) carrier molecules that enable, in particular, the immunogenicity to be augmented ~~argued [sie]~~, via complementary reactive groups carried, respectively, by the carrier molecule and the peptide. By way of example of macromolecular carrier molecules or supports which participate in the constitution of the conjugates according to the invention, there may be mentioned natural proteins such as tetanus toxoid, ovalbumin, serum albumins, haemocyanins, tuberculin PPD (PPD: purified protein derivative), and the like.

Please amend the paragraph beginning at page 12, line 23, as follows:

By way of synthetic macromolecular supports, ~~my~~ [sie] may be mentioned, for example, polylysines or poly(DL-alanine)-poly(L-lysine)s.

Please amend the paragraph beginning at page 12, line 26, as follows:

By way of hydrocarbon or lipid supports, there may be mentioned saturated or unsaturated fatty acids, and preferably C₁₆ to C₁₈ acids of the oleyl [sie] or palmitoleyl [sie] type.

Please amend the paragraph beginning at page 16, line 22, as follows:

The structure of the gene is depicted in Figure 4 and displays the following features:

a) a mini-exon 1 coding at its 3' end for a hydrophobic signal peptide;

b) a short intron (168 basepairs) included between consensus splicing donot and acceptor sites;

c) a second exon of five kilobases which codes for an organized region of 1.8 kilobases, and composed of an arrangement of 7 blocks of 4 amino acids and a 3' hydrophobic region which might correspond to ~~an inking~~ a linking [sie] of the glycosylphosphatidylinositol (GPI) type.

Please amend the title of Example 2 appearing at page 20, lines 20-21 as follows:

Example 2: Protection of immunized chimpanzees against challenge injections [sie] at low or high dose

Please amend the paragraph beginning at page 33, line 4, as follows:

It is clearly apparent that the antibody against the peptide 679 has an almost complete inhibitory effect on the number of what ~~they~~ [sie] was observed at 48 h in the liver cells. Likewise, Figure 7 shows the inhibition of the sporozoite invasion of liver cells by hyperhuman [sie] sera obtained after immunization with different peptides and immunopurified against whole LSA-3.